● TIER 1 — FDA-approved / recognizedGRADE AGLP-1 / incretins & amylin
Liraglutide
GLP-1 RA. Research verification: Yes (TGA pending). 4 human study record(s) in the FitClinicMD studies database.
GOALS · Weight loss
FDA status
Approved: Victoza (T2D ≥10 y), Saxenda (obesity ≥12 y); generics available.
Compounding (503A/503B)
Approved generics available; compounding of copies restricted.
DEA
Not controlled.
WADA (sport)
Not listed on 2026 Prohibited List (no matching section found)
Mechanism
Daily GLP-1RA; t½ ~13 h.
Human evidence · 4
Trial A Randomized, Controlled Trial of Liraglutide for Adolescents with Obesity.
Children/adolescents T2D n=134. Liraglutide in Children and Adolescents with Type 2 Diabetes.
T2D CV outcomes n=9,340: MACE HR 0.87. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes.
Trial A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management.
Reference only. This page summarizes publicly available regulatory and research information about Liraglutide. It is not a prescription, an endorsement, or an offer to dispense, and regulatory status can change. Clinicians should verify current status before prescribing or compounding.